HEADER HYDROLASE 06-JAN-03 1NL6
TITLE CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN
TITLE 2 COMPLEX WITH A COVALENT AZEPANONE INHIBITOR
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: CATHEPSIN K;
COMPND 3 CHAIN: A, B;
COMPND 4 SYNONYM: CATHEPSIN O, CATHEPSIN X, CATHEPSIN O2;
COMPND 5 EC: 3.4.22.38;
COMPND 6 ENGINEERED: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 ORGANISM_TAXID: 9606;
SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA;
SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM;
SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108;
SOURCE 8 EXPRESSION_SYSTEM_CELL_LINE: SF9;
SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS
KEYWDS HYDROLASE, SULFHYDRYL PROTEINASE
EXPDTA X-RAY DIFFRACTION
AUTHOR W.W.SMITH,C.A.JANSON,B.ZHAO
REVDAT 5 13-NOV-24 1NL6 1 REMARK
REVDAT 4 16-AUG-23 1NL6 1 REMARK LINK
REVDAT 3 11-OCT-17 1NL6 1 REMARK
REVDAT 2 24-FEB-09 1NL6 1 VERSN
REVDAT 1 14-JAN-03 1NL6 0
JRNL AUTH R.W.MARQUIS,Y.RU,S.M.LOCASTRO,J.ZENG,D.S.YAMASHITA,H.J.OH,
JRNL AUTH 2 K.F.ERHARD,L.D.DAVIS,T.A.TOMASZEK,D.TEW,K.SALYERS,J.PROKSCH,
JRNL AUTH 3 K.WARD,B.SMITH,M.LEVY,M.D.CUMMINGS,R.C.HALTIWANGER,
JRNL AUTH 4 G.TRESCHER,B.WANG,M.E.HEMLING,C.J.QUINN,H.-Y.CHENG,F.LIN,
JRNL AUTH 5 W.W.SMITH,C.A.JANSON,B.ZHAO,M.S.MCQUENEY,K.D'ALESSIO,
JRNL AUTH 6 C.P.LEE,A.MARZULLI,R.A DODDS,S.BLAKE,S.M.HWANG,I.E.JAMES,
JRNL AUTH 7 C.J.GRESS,B.R.BRADLEY,M.W.LARK,M.GOWEN,D.F.VEBER
JRNL TITL AZEPANONE-BASED INHIBITORS OF HUMAN AND RAT CATHEPSIN K
JRNL REF J.MED.CHEM. V. 44 1380 2001
JRNL REFN ISSN 0022-2623
JRNL PMID 11311061
JRNL DOI 10.1021/JM000481X
REMARK 2
REMARK 2 RESOLUTION. 2.80 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : CNS
REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE-
REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU,
REMARK 3 : READ,RICE,SIMONSON,WARREN
REMARK 3
REMARK 3 REFINEMENT TARGET : ENGH & HUBER
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 6.00
REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000
REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL
REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL
REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 97.0
REMARK 3 NUMBER OF REFLECTIONS : 15561
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING SET) : 0.246
REMARK 3 FREE R VALUE : 0.298
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000
REMARK 3 FREE R VALUE TEST SET COUNT : 1578
REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : NULL
REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.80
REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.83
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 95.00
REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 160
REMARK 3 BIN R VALUE (WORKING SET) : 0.3240
REMARK 3 BIN FREE R VALUE : 0.3680
REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 13.00
REMARK 3 BIN FREE R VALUE TEST SET COUNT : 22
REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 3298
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 104
REMARK 3 SOLVENT ATOMS : 0
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : -21.85800
REMARK 3 B22 (A**2) : 13.55800
REMARK 3 B33 (A**2) : 8.30000
REMARK 3 B12 (A**2) : 0.00000
REMARK 3 B13 (A**2) : 0.00000
REMARK 3 B23 (A**2) : 0.00000
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM SIGMAA (A) : NULL
REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL
REMARK 3
REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM C-V SIGMAA (A) : NULL
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.010
REMARK 3 BOND ANGLES (DEGREES) : 1.390
REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL
REMARK 3 IMPROPER ANGLES (DEGREES) : NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL MODEL : NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA
REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL
REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL
REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL
REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL
REMARK 3
REMARK 3 BULK SOLVENT MODELING.
REMARK 3 METHOD USED : NULL
REMARK 3 KSOL : NULL
REMARK 3 BSOL : NULL
REMARK 3
REMARK 3 NCS MODEL : NULL
REMARK 3
REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT
REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL
REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL
REMARK 3
REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM
REMARK 3 PARAMETER FILE 2 : SB331750.PARAM
REMARK 3 PARAMETER FILE 3 : NULL
REMARK 3 TOPOLOGY FILE 1 : NULL
REMARK 3 TOPOLOGY FILE 2 : NULL
REMARK 3 TOPOLOGY FILE 3 : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 1NL6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-JAN-03.
REMARK 100 THE DEPOSITION ID IS D_1000017971.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 01-MAR-00
REMARK 200 TEMPERATURE (KELVIN) : 100
REMARK 200 PH : 8.0
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : APS
REMARK 200 BEAMLINE : 17-ID
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 1.0
REMARK 200 MONOCHROMATOR : SI 111
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : CCD
REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MAR
REMARK 200 DATA SCALING SOFTWARE : SCALEPACK
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 17372
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.550
REMARK 200 RESOLUTION RANGE LOW (A) : 99.000
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 88.0
REMARK 200 DATA REDUNDANCY : 9.800
REMARK 200 R MERGE (I) : 0.58000
REMARK 200 R SYM (I) : 0.58000
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 32.0000
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.55
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.59
REMARK 200 COMPLETENESS FOR SHELL (%) : 65.0
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : 0.94000
REMARK 200 R SYM FOR SHELL (I) : 0.94000
REMARK 200 <I/SIGMA(I)> FOR SHELL : 9.900
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: CNS
REMARK 200 STARTING MODEL: PDB ENTRY 1ATK
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 63.00
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.32
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: 10% PEG 8000, 0.1 M IMIDAZOLE, 0.2 M
REMARK 280 CALCIUM ACETATE, PH 8.0, VAPOR DIFFUSION, SITTING DROP,
REMARK 280 TEMPERATURE 298K
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X+1/2,-Y,Z+1/2
REMARK 290 3555 -X,Y+1/2,-Z+1/2
REMARK 290 4555 X+1/2,-Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 35.90800
REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 57.42050
REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 37.94400
REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 57.42050
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 35.90800
REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 37.94400
REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1, 2
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 350
REMARK 350 BIOMOLECULE: 2
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: B
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CLOSE CONTACTS
REMARK 500
REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC
REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15
REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A
REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375
REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE
REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS.
REMARK 500
REMARK 500 DISTANCE CUTOFF:
REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS
REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE
REMARK 500 OE2 GLU A 186 N THR B 101 2454 2.14
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 ASP A 3 78.98 -66.82
REMARK 500 PRO A 15 162.40 -48.30
REMARK 500 SER A 24 40.46 -99.08
REMARK 500 GLN A 76 -70.32 -59.19
REMARK 500 GLN A 92 126.02 -177.26
REMARK 500 LYS A 103 119.82 -31.74
REMARK 500 ARG A 108 43.88 -105.27
REMARK 500 ALA A 124 -73.11 -46.00
REMARK 500 VAL A 125 -36.70 -38.92
REMARK 500 PRO A 130 123.19 -39.34
REMARK 500 SER A 146 -26.04 -151.00
REMARK 500 TYR A 151 117.19 172.36
REMARK 500 GLU A 153 6.24 -59.37
REMARK 500 ASN A 161 -3.62 -155.84
REMARK 500 GLN A 172 -90.57 -95.57
REMARK 500 LYS A 173 55.06 -101.09
REMARK 500 ALA A 197 136.97 -38.57
REMARK 500 LYS A 200 59.46 -90.09
REMARK 500 CYS A 204 18.67 47.67
REMARK 500 ALA A 207 51.26 -104.46
REMARK 500 LEU A 209 51.47 -153.88
REMARK 500 ASP B 3 80.25 -67.19
REMARK 500 TYR B 7 -7.17 -51.56
REMARK 500 PRO B 15 161.64 -49.04
REMARK 500 SER B 24 40.28 -99.32
REMARK 500 THR B 42 -1.35 -149.18
REMARK 500 GLN B 92 126.10 -173.29
REMARK 500 LYS B 103 116.94 -35.10
REMARK 500 ALA B 105 178.35 178.08
REMARK 500 ARG B 108 41.35 -106.34
REMARK 500 ALA B 124 -72.76 -43.88
REMARK 500 SER B 146 -25.11 -145.37
REMARK 500 TYR B 151 119.79 173.20
REMARK 500 GLU B 153 8.22 -59.43
REMARK 500 ASN B 161 -6.75 -157.02
REMARK 500 VAL B 164 -168.75 -123.25
REMARK 500 TYR B 169 148.73 -174.31
REMARK 500 GLN B 172 -91.55 -96.03
REMARK 500 LYS B 173 56.22 -100.25
REMARK 500 ALA B 197 137.14 -32.71
REMARK 500 ASN B 199 -0.40 67.62
REMARK 500 CYS B 204 22.51 47.62
REMARK 500 ALA B 207 49.32 -108.91
REMARK 500 LEU B 209 48.91 -147.98
REMARK 500
REMARK 500 REMARK: NULL
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 750 A 501
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 750 B 501
REMARK 900
REMARK 900 RELATED ENTRIES
REMARK 900 RELATED ID: 1ATK RELATED DB: PDB
REMARK 900 CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH THE COVALENT
REMARK 900 INHIBITOR E-64
REMARK 900 RELATED ID: 1AU0 RELATED DB: PDB
REMARK 900 CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT
REMARK 900 SYMMETRIC DIACYLAMINOMETHYL KETONE INHIBITOR
REMARK 900 RELATED ID: 1AU2 RELATED DB: PDB
REMARK 900 CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT
REMARK 900 PROPANONE INHIBITOR
REMARK 900 RELATED ID: 1AU3 RELATED DB: PDB
REMARK 900 CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT
REMARK 900 PYRROLIDINONE INHIBITOR
REMARK 900 RELATED ID: 1AU4 RELATED DB: PDB
REMARK 900 CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT
REMARK 900 PYRROLIDINONE INHIBITOR
DBREF 1NL6 A 1 215 UNP P43235 CATK_HUMAN 115 329
DBREF 1NL6 B 1 215 UNP P43235 CATK_HUMAN 115 329
SEQRES 1 A 215 ALA PRO ASP SER VAL ASP TYR ARG LYS LYS GLY TYR VAL
SEQRES 2 A 215 THR PRO VAL LYS ASN GLN GLY GLN CYS GLY SER CYS TRP
SEQRES 3 A 215 ALA PHE SER SER VAL GLY ALA LEU GLU GLY GLN LEU LYS
SEQRES 4 A 215 LYS LYS THR GLY LYS LEU LEU ASN LEU SER PRO GLN ASN
SEQRES 5 A 215 LEU VAL ASP CYS VAL SER GLU ASN ASP GLY CYS GLY GLY
SEQRES 6 A 215 GLY TYR MET THR ASN ALA PHE GLN TYR VAL GLN LYS ASN
SEQRES 7 A 215 ARG GLY ILE ASP SER GLU ASP ALA TYR PRO TYR VAL GLY
SEQRES 8 A 215 GLN GLU GLU SER CYS MET TYR ASN PRO THR GLY LYS ALA
SEQRES 9 A 215 ALA LYS CYS ARG GLY TYR ARG GLU ILE PRO GLU GLY ASN
SEQRES 10 A 215 GLU LYS ALA LEU LYS ARG ALA VAL ALA ARG VAL GLY PRO
SEQRES 11 A 215 VAL SER VAL ALA ILE ASP ALA SER LEU THR SER PHE GLN
SEQRES 12 A 215 PHE TYR SER LYS GLY VAL TYR TYR ASP GLU SER CYS ASN
SEQRES 13 A 215 SER ASP ASN LEU ASN HIS ALA VAL LEU ALA VAL GLY TYR
SEQRES 14 A 215 GLY ILE GLN LYS GLY ASN LYS HIS TRP ILE ILE LYS ASN
SEQRES 15 A 215 SER TRP GLY GLU ASN TRP GLY ASN LYS GLY TYR ILE LEU
SEQRES 16 A 215 MET ALA ARG ASN LYS ASN ASN ALA CYS GLY ILE ALA ASN
SEQRES 17 A 215 LEU ALA SER PHE PRO LYS MET
SEQRES 1 B 215 ALA PRO ASP SER VAL ASP TYR ARG LYS LYS GLY TYR VAL
SEQRES 2 B 215 THR PRO VAL LYS ASN GLN GLY GLN CYS GLY SER CYS TRP
SEQRES 3 B 215 ALA PHE SER SER VAL GLY ALA LEU GLU GLY GLN LEU LYS
SEQRES 4 B 215 LYS LYS THR GLY LYS LEU LEU ASN LEU SER PRO GLN ASN
SEQRES 5 B 215 LEU VAL ASP CYS VAL SER GLU ASN ASP GLY CYS GLY GLY
SEQRES 6 B 215 GLY TYR MET THR ASN ALA PHE GLN TYR VAL GLN LYS ASN
SEQRES 7 B 215 ARG GLY ILE ASP SER GLU ASP ALA TYR PRO TYR VAL GLY
SEQRES 8 B 215 GLN GLU GLU SER CYS MET TYR ASN PRO THR GLY LYS ALA
SEQRES 9 B 215 ALA LYS CYS ARG GLY TYR ARG GLU ILE PRO GLU GLY ASN
SEQRES 10 B 215 GLU LYS ALA LEU LYS ARG ALA VAL ALA ARG VAL GLY PRO
SEQRES 11 B 215 VAL SER VAL ALA ILE ASP ALA SER LEU THR SER PHE GLN
SEQRES 12 B 215 PHE TYR SER LYS GLY VAL TYR TYR ASP GLU SER CYS ASN
SEQRES 13 B 215 SER ASP ASN LEU ASN HIS ALA VAL LEU ALA VAL GLY TYR
SEQRES 14 B 215 GLY ILE GLN LYS GLY ASN LYS HIS TRP ILE ILE LYS ASN
SEQRES 15 B 215 SER TRP GLY GLU ASN TRP GLY ASN LYS GLY TYR ILE LEU
SEQRES 16 B 215 MET ALA ARG ASN LYS ASN ASN ALA CYS GLY ILE ALA ASN
SEQRES 17 B 215 LEU ALA SER PHE PRO LYS MET
HET 750 A 501 52
HET 750 B 501 52
HETNAM 750 5-(2-MORPHOLIN-4-YLETHOXY)BENZOFURAN-2-CARBOXYLIC ACID
HETNAM 2 750 ((S)-3-METHYL-1-{(S)-3-OXO-1-[2-(3-PYRIDIN-2-
HETNAM 3 750 YLPHENYL)ACETYL]AZEPAN-4-YLCARBAMOYL}BUTYL)AMIDE
FORMUL 3 750 2(C40 H47 N5 O7)
HELIX 1 1 TYR A 7 GLY A 11 1 5
HELIX 2 2 SER A 24 GLY A 43 1 20
HELIX 3 3 SER A 49 VAL A 57 1 9
HELIX 4 4 ASP A 61 GLY A 65 5 5
HELIX 5 5 MET A 68 ARG A 79 1 12
HELIX 6 6 ASN A 99 LYS A 103 5 5
HELIX 7 7 ASN A 117 GLY A 129 1 13
HELIX 8 8 LEU A 139 PHE A 144 1 6
HELIX 9 9 ASN A 202 ILE A 206 5 5
HELIX 10 10 TYR B 7 GLY B 11 1 5
HELIX 11 11 SER B 24 GLY B 43 1 20
HELIX 12 12 SER B 49 VAL B 57 1 9
HELIX 13 13 ASP B 61 GLY B 65 5 5
HELIX 14 14 MET B 68 ARG B 79 1 12
HELIX 15 15 ASN B 99 LYS B 103 5 5
HELIX 16 16 ASN B 117 GLY B 129 1 13
HELIX 17 17 LEU B 139 PHE B 144 1 6
HELIX 18 18 ASN B 202 ILE B 206 5 5
SHEET 1 A 5 VAL A 149 TYR A 150 0
SHEET 2 A 5 TYR A 193 ALA A 197 1 O LEU A 195 N TYR A 150
SHEET 3 A 5 LYS A 176 LYS A 181 -1 N ILE A 180 O ILE A 194
SHEET 4 A 5 HIS A 162 ILE A 171 -1 N GLY A 170 O HIS A 177
SHEET 5 A 5 VAL A 5 ASP A 6 -1 N VAL A 5 O TYR A 169
SHEET 1 B 5 VAL A 149 TYR A 150 0
SHEET 2 B 5 TYR A 193 ALA A 197 1 O LEU A 195 N TYR A 150
SHEET 3 B 5 LYS A 176 LYS A 181 -1 N ILE A 180 O ILE A 194
SHEET 4 B 5 HIS A 162 ILE A 171 -1 N GLY A 170 O HIS A 177
SHEET 5 B 5 VAL A 131 ILE A 135 -1 N ILE A 135 O HIS A 162
SHEET 1 C 2 TYR A 110 GLU A 112 0
SHEET 2 C 2 SER A 211 PRO A 213 -1 O PHE A 212 N ARG A 111
SHEET 1 D 5 VAL B 149 TYR B 150 0
SHEET 2 D 5 TYR B 193 ALA B 197 1 O LEU B 195 N TYR B 150
SHEET 3 D 5 LYS B 176 LYS B 181 -1 N ILE B 180 O ILE B 194
SHEET 4 D 5 HIS B 162 ALA B 166 -1 N LEU B 165 O LYS B 181
SHEET 5 D 5 VAL B 131 ILE B 135 -1 N ILE B 135 O HIS B 162
SHEET 1 E 5 VAL B 149 TYR B 150 0
SHEET 2 E 5 TYR B 193 ALA B 197 1 O LEU B 195 N TYR B 150
SHEET 3 E 5 LYS B 176 LYS B 181 -1 N ILE B 180 O ILE B 194
SHEET 4 E 5 GLY B 168 ILE B 171 -1 N GLY B 170 O HIS B 177
SHEET 5 E 5 VAL B 5 ASP B 6 -1 N VAL B 5 O TYR B 169
SHEET 1 F 2 TYR B 110 GLU B 112 0
SHEET 2 F 2 SER B 211 PRO B 213 -1 O PHE B 212 N ARG B 111
SSBOND 1 CYS A 22 CYS A 63 1555 1555 2.02
SSBOND 2 CYS A 56 CYS A 96 1555 1555 2.05
SSBOND 3 CYS A 155 CYS A 204 1555 1555 2.04
SSBOND 4 CYS B 22 CYS B 63 1555 1555 2.03
SSBOND 5 CYS B 56 CYS B 96 1555 1555 2.04
SSBOND 6 CYS B 155 CYS B 204 1555 1555 2.04
LINK SG CYS A 25 C31 750 A 501 1555 1555 1.79
LINK SG CYS B 25 C31 750 B 501 1555 1555 1.82
SITE 1 AC1 22 GLN A 19 GLY A 20 CYS A 22 GLY A 23
SITE 2 AC1 22 SER A 24 CYS A 25 TRP A 26 SER A 58
SITE 3 AC1 22 GLU A 59 GLY A 65 GLY A 66 TYR A 67
SITE 4 AC1 22 ALA A 134 LEU A 160 ASN A 161 HIS A 162
SITE 5 AC1 22 TRP A 184 TRP A 188 TYR B 67 THR B 69
SITE 6 AC1 22 GLU B 112 LEU B 209
SITE 1 AC2 24 TYR A 67 THR A 69 GLU A 112 LEU A 209
SITE 2 AC2 24 GLN B 19 GLY B 20 CYS B 22 GLY B 23
SITE 3 AC2 24 SER B 24 CYS B 25 TRP B 26 LYS B 41
SITE 4 AC2 24 THR B 42 SER B 58 GLU B 59 GLY B 65
SITE 5 AC2 24 GLY B 66 TYR B 67 ALA B 134 LEU B 160
SITE 6 AC2 24 ASN B 161 HIS B 162 TRP B 184 TRP B 188
CRYST1 71.816 75.888 114.841 90.00 90.00 90.00 P 21 21 21 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.013924 0.000000 0.000000 0.00000
SCALE2 0.000000 0.013177 0.000000 0.00000
SCALE3 0.000000 0.000000 0.008708 0.00000